SGLT2 Inhibitors Safe for KTRs, Data Show
The safety profile of SGLT2 inhibitors in kidney transplant recipients with type 2 diabetes is similar to that of other patient populations, new research suggests.
The safety profile of SGLT2 inhibitors in kidney transplant recipients with type 2 diabetes is similar to that of other patient populations, new research suggests.
How outcomes differ between recipients of deceased vs living donor kidneys of advanced age needs to be studied further.
Although valganciclovir is an effective CMV prophylactic agent after kidney transplantation, it is associated with significant side effects.
Effective therapy of post-transplant membranous nephropathy may improve outcomes.
The current US Kidney Allocation System (KAS) may disadvantage waitlist candidates already receiving dialysis, according to investigators.
In a study, aviremic recipients of HCV-positive and HCV-negative deceased donor kidneys had similar 12-month transplant outcomes.
A growing body of research supports harvesting and transplanting of donor acute kidney injury kidneys.
The increased death risk associated with type 2 diabetes in kidney transplant recipients does not vary significantly by body mass index, according to investigators.
Study findings “have implications for development of SOT-specific approaches for risk stratification that may be applied to patient evaluation and triage,” according to investigators.
Performing dual deceased donor kidney transplantations may maximize use of suboptimal kidneys, according to investigators.